Conference Coverage
Conference Coverage
New agents for youth-onset type 2 diabetes ‘finally in sight’
‘A number of clinical trials of antidiabetic pharmacologic agents in diabetic youth have been completed, demonstrating safety and efficacy, and a...
Conference Coverage
Testosterone replacement shows CV benefit in hypogonadal men
Among men with hypogonadism who received testosterone replacement every 3 months, cardiovascular parameters were better and there were fewer...
Conference Coverage
Not so crazy: Pancreas transplants in type 2 diabetes rising
Simultaneous pancreas-kidney transplants are increasingly performed in patients with type 2 diabetes and chronic kidney disease.
Conference Coverage
OSA in women: Different symptoms, risks and consequences
Conference Coverage
Heart failure med undertreatment because of older age common, flouts evidence
The oldest less often received guideline-specified meds, especially at close to full dosage, maybe because advanced age is seen as an “intrinsic”...
Conference Coverage
What’s best for diabetes after metformin? GRADE outdated at outset
The GRADE trial compared four different agents as add-ons to metformin for type 2 diabetes, but the study is already outdated, said one...
Conference Coverage
‘Praise Diabetes’: Support programs in Black churches yield lasting A1c changes
Statistically significant reductions in A1c and diabetes distress were seen in the Praise Diabetes Project, a 33-month randomized trial, an...
Conference Coverage
EAS lipid guidance: Start high-risk patients on combo drug
Instead of starting very-high-risk patients unlikely to reach goal on a statin alone, clinicians should immediately reach for combination statin-...
Conference Coverage
AMPLITUDE-O: Efpeglenatide benefits in high-risk diabetes
In older patients with long-time type 2 diabetes and CVD or kidney disease, the investigational GLP-1 agonist efpeglenatide was safe and lowered...
Conference Coverage
Semaglutide 2.4 mg ‘likely to usher in a new era’ in obesity treatment
Clinical experience with this drug will grow rapidly over the next few years, one expert predicts, and new combination drugs are near, so...
Conference Coverage
Nocturnal hypoglycemia halved with insulin degludec vs. glargine
Researchers pitted degludec against glargine U100 in the toughest patients with type 1 diabetes, those who had severe nocturnal hypoglycemia.